Risks of ACE Inhibitor and ARB Usage in COVID‐19: Evaluating the Evidence

Author:

Sriram Krishna1,Insel Paul A.12

Affiliation:

1. Department of Pharmacology University of California San Diego La Jolla California USA

2. Department of Medicine University of California San Diego La Jolla California USA

Funder

University of California

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference53 articles.

1. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

2. Rapid response: use of angiotensin receptor blockers such as Telmisartan, Losartsan in nCoV Wuhan Corona Virus infections—novel mode of treatment. Response to the emerging novel coronavirus outbreak;Phadke M.;BMJ,2020

3. Lewis E.ACE‐inhibitors ARBs and COVID‐19: what GPs need to know. Royal Australian College of General Practitioners (RACGP) Feature March 18 2020 (2020).

4. COVID‐19 and angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?;Patel A.B.;JAMA

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3